Our results indicate that in prostate cancer, docetaxel treatment represses KLF5 expression through AMPK/mTOR/p70S6K signaling pathway, which may lead to increase of BECN1, induction of cell autophagy, and promotion of cell survival. This evidence concerns the gene KLF5 and prostate cancer.